e-learning
resources
Munich 2006
Monday 04.09.2006
Recent advances in the treatment of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy and tolerability of tetomilast, a new inhibitor of neutrophilic inflammation, in chronic obstructive pulmonary disease
N. A. Molfino, S. Mallikaarjun, P. Zhang, S. Shoaf, K. Mitsui (Rockville, United States Of America)
Source:
Annual Congress 2006 - Recent advances in the treatment of COPD
Session:
Recent advances in the treatment of COPD
Session type:
Oral Presentation
Number:
3048
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. A. Molfino, S. Mallikaarjun, P. Zhang, S. Shoaf, K. Mitsui (Rockville, United States Of America). Efficacy and tolerability of tetomilast, a new inhibitor of neutrophilic inflammation, in chronic obstructive pulmonary disease. Eur Respir J 2006; 28: Suppl. 50, 3048
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2006; 28: Suppl. 50, 527s
Year: 2006
Fenspiride efficacy in the treatment of chronic obstructive pulmonary disease
Source: International Congress 2017 – Novel mechanisms and treatments for COPD
Year: 2017
Efficacy of lasolvan in the treatment of patients with chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
Inferon efficacy in the treatment of chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD
Year: 2008
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 74-81
Year: 2003
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Source: Eur Respir J 2003; 21: 912
Year: 2003
Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
Safety and effectiveness of sputum induction in chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: Suppl. 33, 67s
Year: 2001
Modulation of airway inflammation to prevent exacerbations of COPD
Source: Eur Respir Rev 2005; 14: 78-82
Year: 2005
Cilomilast is efficacious in chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2003; 22: Suppl. 45, 68s
Year: 2003
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 217-224
Year: 2002
Beyond corticosteroids: future prospects in the management of inflammation in COPD
Source: Eur Respir Rev 2011; 20: 175-182
Year: 2011
Comparison of the efficacy of azythromycin and roxithromycin in the treatment of acute purulent exacerbation of chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: Suppl. 33, 138s
Year: 2001
The efficacy and treatment length of oral corticosteroids in patient with acute exacerbation of chronic obstructive pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 295s
Year: 2005
Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline
Source: Annual Congress 2005 - Therapeutic options for COPD: present and future
Year: 2005
Efficacy and safety of bacterial lysates in patients with chronic obstructive pulmonary disease and exacerbation
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 515s
Year: 2001
Mucoactive therapy in COPD
Source: Eur Respir Rev 2009; 19: 134-140
Year: 2010
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001
Systemic effects of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 347-360
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept